These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 31950853)

  • 21. Severe and acute complications of biologics in psoriasis.
    Oussedik E; Patel NU; Cash DR; Gupta AS; Feldman SR
    G Ital Dermatol Venereol; 2017 Dec; 152(6):586-596. PubMed ID: 28895664
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis.
    Leman J; Burden AD
    Br J Dermatol; 2012 Nov; 167 Suppl 3():12-20. PubMed ID: 23082811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug survival of biologic treatments in psoriasis: a systematic review.
    No DJ; Inkeles MS; Amin M; Wu JJ
    J Dermatolog Treat; 2018 Aug; 29(5):460-466. PubMed ID: 29076754
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Ramaekers BLT; Wolff RF; Pouwels X; Oosterhoff M; Van Giessen A; Worthy G; Noake C; Armstrong N; Kleijnen J; Joore MA
    Pharmacoeconomics; 2018 Aug; 36(8):917-927. PubMed ID: 29480455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of severe psoriasis with TNF antagonists. Adalimumab, etanercept and infliximab.
    Mössner R; Reich K
    Curr Probl Dermatol; 2009; 38():107-136. PubMed ID: 19710553
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Japanese guidance for use of biologics for psoriasis (the 2019 version).
    Saeki H; Terui T; Morita A; Sano S; Imafuku S; Asahina A; Komine M; Etoh T; Igarashi A; Torii H; Abe M; Nakagawa H; Watanabe A; Yotsuyanagi H; Ohtsuki M;
    J Dermatol; 2020 Mar; 47(3):201-222. PubMed ID: 31916326
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current biological therapies for use in HIV-positive patients with psoriasis: case report of gesulkumab used and review.
    Bartos G; Cline A; Beroukhim K; Burrall BA; Feldman SR
    Dermatol Online J; 2018 Nov; 24(11):. PubMed ID: 30695971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biologic Therapy in Psoriasis (Part I): Efficacy and Safety of Tumor Necrosis Factor- α Inhibitors.
    Campanati A; Molinelli E; Brisigotti V; Offidani A
    Curr Pharm Biotechnol; 2017; 18(12):945-963. PubMed ID: 29424306
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Role of Biologic Therapies in Dermatology.
    Fathi R; Armstrong AW
    Med Clin North Am; 2015 Nov; 99(6):1183-94. PubMed ID: 26476247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.
    Mason KJ; Barker JNWN; Smith CH; Hampton PJ; Lunt M; McElhone K; Warren RB; Yiu ZZN; Griffiths CEM; Burden AD;
    JAMA Dermatol; 2018 May; 154(5):581-588. PubMed ID: 29590279
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study.
    Viguier M; Pagès C; Aubin F; Delaporte E; Descamps V; Lok C; Beylot-Barry M; Séneschal J; Dubertret L; Morand JJ; Dréno B; Bachelez H;
    Br J Dermatol; 2012 Aug; 167(2):417-23. PubMed ID: 22413927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biologic therapy in psoriasis: perspectives on associated risks and patient management.
    Papp KA; Dekoven J; Parsons L; Pirzada S; Robern M; Robertson L; Tan JK
    J Cutan Med Surg; 2012; 16(3):153-68. PubMed ID: 22713438
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Biologic therapies in the treatment of psoriasis].
    Farhi D; Dupin N
    Presse Med; 2009 May; 38(5):832-43. PubMed ID: 19282134
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: A systematic review and network meta-analysis.
    Lu C; Wallace BI; Waljee AK; Fu W; Zhang Q; Liu Y
    Semin Arthritis Rheum; 2019 Dec; 49(3):381-388. PubMed ID: 31272807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris.
    Gniadecki R; Bang B; Bryld LE; Iversen L; Lasthein S; Skov L
    Br J Dermatol; 2015 Jan; 172(1):244-52. PubMed ID: 25132294
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?
    Langley RG
    J Eur Acad Dermatol Venereol; 2012 Mar; 26 Suppl 2():21-9. PubMed ID: 22356632
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of biologics in psoriasis.
    Kamata M; Tada Y
    J Dermatol; 2018 Mar; 45(3):279-286. PubMed ID: 29226369
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of erythrodermic psoriasis with biologics: A systematic review.
    Carrasquillo OY; Pabón-Cartagena G; Falto-Aizpurua LA; Santiago-Vázquez M; Cancel-Artau KJ; Arias-Berrios G; Martín-García RF
    J Am Acad Dermatol; 2020 Jul; 83(1):151-158. PubMed ID: 32247872
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biologics switch in psoriasis.
    Wang TS; Tsai TF
    Immunotherapy; 2019 Apr; 11(6):531-541. PubMed ID: 31135243
    [No Abstract]   [Full Text] [Related]  

  • 40. Safety of Systemic Agents for the Treatment of Pediatric Psoriasis.
    Bronckers IMGJ; Seyger MMB; West DP; Lara-Corrales I; Tollefson M; Tom WL; Hogeling M; Belazarian L; Zachariae C; Mahé E; Siegfried E; Philipp S; Szalai Z; Vleugels RA; Holland K; Murphy R; Baselga E; Cordoro K; Lambert J; Alexopoulos A; Mrowietz U; Kievit W; Paller AS;
    JAMA Dermatol; 2017 Nov; 153(11):1147-1157. PubMed ID: 28903160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.